RevMed's pancreatic cancer drug Rasonque generates $198M in Q3, far exceeding forecasts

RevMed reported $198 million in revenue from its newly launched pancreatic cancer therapy Rasonque during the third quarter, roughly ten times the $19 million estimate from Truist Securities.

The sales were driven by treatment of more than 5,000 patients within five weeks of the drug's late‑August approval for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are unsuitable for multi‑agent regimens.

Analysts highlighted the pent‑up demand for a RAS inhibitor in a disease with limited options, calling the launch impressive and suggesting a significant market impact moving forward.